HC Wainwright Issues Positive Outlook for enGene Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for enGene in a research note issued on Tuesday, June 16th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.56). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.97) per share. HC Wainwright also issued estimates for enGene’s Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($0.77) EPS and FY2030 earnings at ($0.22) EPS.

enGene (NASDAQ:ENGN) last issued its earnings results on Monday, June 15th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same period last year, the company posted $0.51 earnings per share.

A number of other research analysts have also recently issued reports on the company. Guggenheim cut enGene from a “buy” rating to a “neutral” rating in a research report on Thursday, May 7th. Weiss Ratings cut shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Leerink Partners lowered shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a report on Friday, May 8th. Citigroup cut shares of enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Finally, Piper Sandler downgraded shares of enGene from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $7.00 to $4.00 in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $11.05.

enGene Price Performance

Shares of ENGN stock opened at $1.74 on Thursday. The company has a quick ratio of 11.75, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The company has a market cap of $116.56 million, a P/E ratio of -0.80 and a beta of -0.30. The business has a fifty day simple moving average of $4.10 and a 200 day simple moving average of $7.10.

Institutional Investors Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC increased its position in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after acquiring an additional 3,771,840 shares during the period. Siren L.L.C. lifted its holdings in shares of enGene by 57.5% during the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after purchasing an additional 1,916,895 shares during the period. Cormorant Asset Management LP lifted its holdings in shares of enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after purchasing an additional 1,676,405 shares during the period. Blue Owl Capital Holdings LP grew its stake in shares of enGene by 2.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock worth $30,349,000 after purchasing an additional 82,831 shares during the last quarter. Finally, Braidwell LP increased its holdings in enGene by 38.2% in the fourth quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after purchasing an additional 865,000 shares during the period. 64.16% of the stock is owned by institutional investors.

Key Stories Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on enGene Holdings Inc. (ENGN) and maintained a $4.00 price target, signaling continued analyst confidence in the stock. ENGN analyst coverage
• Positive Sentiment: The analyst improved earnings estimates for FY2026, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029, suggesting losses may be narrowing faster than previously expected. ENGN estimate revisions
• Neutral Sentiment: HC Wainwright cut its FY2030 EPS estimate, which tempers the otherwise better near-term outlook. ENGN estimate revisions

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.